Specifically, CDK4/6 inhibitors andnonspecific BRD inhibitors were shown to act on both T-cell and tumor cellcompartments by (1) increasing the release of T-cell cytolytic granules andinterferon-gamma (IFNg) and (2) upregulating tumor cell MHC expression, antigenpresentation, and IFNg secretion. This evidence concerns the gene CDK4 and neoplasm.